Can You Continue Chemotherapy With Blood Clots?

In most cases, chemotherapy can and does continue after a blood clot is diagnosed. The standard approach is to start anticoagulation therapy alongside ongoing cancer treatment rather than suspend chemotherapy, because delaying cancer care carries its own serious risks. That said, the decision is never automatic. It depends on the type and location of the clot, the specific chemotherapy regimen, your platelet count, kidney function, and the bleeding risks involved. Blood clots during cancer treatment are common enough that oncology guidelines address the scenario directly, and the clinical infrastructure for managing both at once is well established.

Why Blood Clots and Chemotherapy Go Hand in Hand

Cancer itself pushes the body toward clotting. Tumors release substances that activate the clotting cascade, and cancer patients often deal with reduced mobility, surgery, and central venous catheters, all of which raise clot risk further. Venous thromboembolism, which includes deep vein thrombosis in the legs and pulmonary embolism in the lungs, is the most common type of clot in cancer patients and a major cause of death in this population.¹ Chemotherapy compounds the problem. It damages blood vessel linings, lowers natural anticoagulant proteins, and can increase platelet activation.

So when a blood clot shows up during treatment, oncologists are rarely surprised. The question is not whether to treat the clot but how to manage it without derailing the cancer therapy. For most patients, the answer involves starting a blood thinner and continuing chemotherapy on schedule.

Which Chemotherapy Drugs Raise Clot Risk the Most

Not all chemo drugs carry equal clot risk, and knowing which regimens are the biggest offenders matters for understanding why your medical team may already be watching for clots before they happen.

Cisplatin is one of the most well-known culprits. It damages the inner lining of blood vessels and triggers platelet activation, both of which tip the balance toward clot formation.² Bevacizumab, a targeted therapy used in colorectal cancer, lung cancer, and other solid tumors, raises the risk of both arterial and venous clots. In patients with colorectal cancer, those receiving bevacizumab had a roughly 33% higher overall rate of clot events compared to those who did not.³ In prostate cancer, bevacizumab roughly tripled the risk of serious arterial clot events compared to placebo.⁴

Immunomodulatory drugs used in multiple myeloma deserve special mention. Patients with myeloma already face up to a 20-fold increased clot risk compared to the general population, and drugs like thalidomide and lenalidomide amplify it further.⁵ On their own, these drugs add modest risk. But when combined with high-dose dexamethasone, the clot rate can reach around 26%.⁶ That is why myeloma patients on these regimens are almost always placed on preventive blood thinners from the start.⁷

How Blood Clots Are Treated During Chemotherapy

The backbone of treatment is anticoagulation, and the landscape has shifted in recent years. For a long time, low-molecular-weight heparin injections were the go-to choice for cancer patients with clots, largely because the landmark CLOT trial showed they worked better than the older oral blood thinner warfarin in this population. More recently, direct oral anticoagulants, the pills many people recognize as rivaroxaban, apixaban, or edoxaban, have entered the picture. Clinical trials showed that these pills prevented recurrent clots at least as effectively as heparin injections, and in some studies slightly better, though with a trade-off of somewhat more bleeding in certain groups.⁸

A large comparative study found that patients on oral anticoagulants had lower rates of recurrent clots than those on heparin injections or warfarin, roughly 21 events per 100 person-years versus 40 for heparin and 30 for warfarin.⁹ Heparin injections were also associated with more than double the rate of hospitalizations for major bleeding compared to oral anticoagulants in the same study.⁹

From a practical standpoint, the shift toward oral anticoagulants has made life easier for patients managing both chemo and clot treatment. Patients report substantially higher satisfaction with pills than with daily self-injections, with satisfaction rates in the range of 75% to 83% for oral anticoagulants compared to 45% to 65% for injections, and adherence improves meaningfully as well.¹⁰

When Oral Anticoagulants Are Not the Best Choice

The convenience of oral anticoagulants does not make them universally appropriate during cancer treatment. Gastrointestinal cancers are a particular concern. In patients with upper GI tumors, the five-year rate of major bleeding on oral anticoagulants was roughly 22%, compared to about 12% in patients with non-GI cancers.¹¹ Unresected GI tumors in particular carry a dramatically elevated bleeding risk, with one multicenter study finding they increased the odds of major bleeding more than sevenfold compared to other cancer types.¹² For these patients, heparin injections remain the safer choice because the dose can be adjusted more easily and the drug clears the body faster if bleeding starts.

Drug interactions also complicate the picture. Many chemotherapy agents and supportive medications affect the same liver enzymes and transport proteins that process oral anticoagulants. These interactions can push anticoagulant levels too high, increasing bleeding risk, or too low, leaving patients unprotected against new clots. Interactions like these have been identified as a reason to withhold oral anticoagulants and choose an alternative.¹³ Your oncologist and pharmacist will typically review your full medication list before deciding which blood thinner fits your situation.

Concurrent use of steroids, which are common in many chemo regimens as anti-nausea medications or as part of the treatment itself, also raises the bleeding risk when combined with oral anticoagulants. One real-world analysis found that steroid use roughly tripled the rate of major bleeding in patients on these drugs.¹²

Low Platelet Counts Make Everything Harder

Many chemotherapy regimens temporarily suppress the bone marrow, which can cause platelet counts to drop. Platelets are the cells that help form clots to stop bleeding, so a person with very low platelets is already at heightened risk of hemorrhage. Paradoxically, low platelet counts in cancer patients do not protect against new blood clots forming.¹⁴ You can be at risk for both excessive clotting and excessive bleeding at the same time, which is one of the trickiest situations in cancer care.

There are no large, high-quality trials telling clinicians exactly what to do when a patient has a blood clot and a dangerously low platelet count simultaneously. The approach is individualized: the team weighs the risk of the clot growing or breaking loose against the risk of a bleed, often adjusting anticoagulant doses day by day and sometimes pausing treatment temporarily when platelet counts hit their lowest point during a chemo cycle. In some cases, this balancing act is the factor that leads to a brief chemotherapy delay, not because clots and chemo are incompatible in principle, but because the platelet situation needs to stabilize first.

Kidney Function and Bleeding Risk

Reduced kidney function is another variable that influences how blood thinners are managed during chemotherapy. Some chemotherapy drugs are hard on the kidneys, and if kidney function declines, blood thinners can accumulate to dangerous levels. This is especially true of heparin injections, which are cleared through the kidneys. In patients with severe kidney impairment, the rate of fatal bleeding on heparin injections was more than 15 times higher than in patients with normal kidney function.¹⁵ Even moderate kidney impairment roughly doubled the risk of major bleeding events on heparin. These findings underscore why kidney function gets monitored closely throughout treatment. If kidneys start to struggle, the team may switch the type or dose of blood thinner rather than stopping chemo.

Pulmonary Embolism During Cancer Treatment

A pulmonary embolism, where a clot lodges in the lungs, is the most dangerous form of venous blood clot. In cancer patients, PE is a medical emergency associated with a high rate of early death, including sudden death in a quarter of cases.¹⁶ The severity matters enormously. A small clot found incidentally on a CT scan done for cancer staging is managed differently from a massive clot that causes the heart to strain.

Incidental pulmonary embolisms, caught on scans ordered for other reasons, are common in cancer patients. In one study, about 79% of patients with incidentally discovered PE were on active cancer treatment at the time, mostly chemotherapy, and the vast majority were started on anticoagulation without stopping their cancer therapy.¹⁷

For larger, hemodynamically significant pulmonary embolisms, catheter-based interventions are an option. National data suggest that catheter-based treatment for intermediate- or high-risk PE in cancer patients is associated with lower in-hospital death compared to medical therapy alone, though with a somewhat higher rate of procedural bleeding.¹⁸ Compared to systemic clot-busting drugs, catheter-based approaches were actually associated with lower rates of major bleeding in a separate analysis of over 7,700 cancer patients.¹⁹ In practice, chemotherapy may be briefly paused during the acute management of a serious PE, but the goal is to resume as soon as the patient is stabilized and safely anticoagulated.

How Blood Clots Affect Cancer Prognosis

Beyond the immediate danger of the clot itself, developing a blood clot during cancer treatment is an independent marker of worse outcomes. A large Scandinavian study found that cancer patients who developed venous clots had a 3.4-fold higher mortality risk than cancer patients who did not, and this held true across all cancer types studied.²⁰ The reasons are not fully understood. Part of it is that clots themselves can be fatal. Part of it is that the biological aggressiveness that makes certain cancers more dangerous also makes them more prone to triggering clots. And part of it is that clots can force treatment modifications or hospitalizations that interrupt cancer therapy.

This is precisely why continuing chemotherapy after a blood clot, rather than pausing indefinitely, matters so much. An untreated or undertreated cancer is a greater long-term threat than a clot that is being managed with appropriate anticoagulation. The medical team’s calculus is usually that the survival benefit of continued cancer treatment outweighs the added complexity of managing a blood thinner at the same time.

Preventive Blood Thinners During Chemotherapy

For patients who have not yet developed a clot but are at high risk, preventive anticoagulation during chemotherapy is an option. Guidelines recommend considering preventive blood thinners for ambulatory cancer patients starting chemotherapy who score as intermediate or high risk on validated assessment tools like the Khorana score.²¹ The Khorana score accounts for cancer type, blood counts, and body mass index to estimate clot risk before treatment begins.

Preventive anticoagulation is not prescribed for every chemotherapy patient. The balance tips in favor of prevention primarily for those on regimens known to carry high clot risk, such as cisplatin-based combinations for solid tumors or immunomodulatory drugs for myeloma. For lower-risk patients, the bleeding risk of a blood thinner may outweigh the benefit. After major abdominal or pelvic cancer surgery followed by chemotherapy, extended preventive anticoagulation with oral agents appears to be as safe and effective as heparin injections for preventing post-operative clots.²²

When a New Clot Forms Despite Anticoagulation

One of the more frustrating scenarios is developing a new blood clot while already taking a blood thinner. This happens more often in cancer patients than in other populations, because the underlying disease keeps driving clot formation even when anticoagulation is on board. The management of these cases is complex and may involve switching the type of anticoagulant, increasing the dose, or adding a mechanical intervention like a filter placed in the large vein leading to the heart to physically trap clots before they reach the lungs.²³

Even in this scenario, the default is usually to continue chemotherapy. The reasoning does not change: cancer progression remains the primary threat, and the clot management strategy simply gets escalated. Chemotherapy might be paused briefly during the acute adjustment period, particularly if the new clot is a serious pulmonary embolism, but the intention is almost always to resume.

Situations Where Chemotherapy Genuinely Pauses

While the overall theme is that chemo continues, there are situations where a temporary delay is the right call. A massive pulmonary embolism requiring intensive care, hemodynamic instability, or catheter-based intervention usually means a brief treatment break until the patient is stable. Severe thrombocytopenia at the bottom of a chemo cycle, combined with a new clot requiring anticoagulation, can create a window where both chemo and full-dose blood thinners carry unacceptable bleeding risk simultaneously. Active, uncontrolled bleeding from any cause will pause both the blood thinner and chemotherapy until the bleeding is resolved.

These pauses tend to be measured in days to a couple of weeks, not months. The oncology team monitors the situation closely and restarts treatment as soon as the acute crisis is managed. A permanent stop to chemotherapy solely because of a blood clot would be unusual and would typically reflect other complicating factors like overall declining health rather than the clot alone.

Clots in Chemotherapy Catheters

Many chemotherapy patients receive treatment through a centrally placed catheter, such as a port or a PICC line. These devices sit inside veins for weeks or months, and the foreign surface can trigger clot formation around the catheter itself. Catheter-related clots are a distinct problem from deep vein thrombosis or pulmonary embolism. They are usually treated with anticoagulation, and in most cases the catheter can stay in place if it is still functioning and still needed for treatment. Removal becomes necessary if the catheter is infected, if the clot is not responding to blood thinners, or if the catheter is no longer essential. Chemotherapy continues through alternative access if the catheter must come out, or simply continues through the same catheter if it remains usable.

Guidelines across major oncology organizations are broadly aligned on the fundamentals of managing cancer-related clots, though they differ on some specifics, such as which oral anticoagulant to prefer or how long to continue anticoagulation after the acute phase.²⁴ What they agree on is that cancer treatment should not be abandoned because of a treatable clot. The tools to manage both problems simultaneously exist and are used routinely. If you develop a clot during chemotherapy, the conversation with your oncologist will almost certainly be about how to treat the clot while keeping your cancer therapy on track, not whether to choose between the two.